Webvent

SCRS Resource Guide Network

Sites, Sponsors, CROs: Discover the solutions your clinical research teams need with SCRS.

Bioclinica

Leader in Clinical Trial Management Solutions

Bioclinica
Header

Bioclinica is divided into three business segments so that we can provide expert service and multifaceted technologies.

Our Medical Imaging and Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Biomarker Laboratory.

Our eHealth segment comprises an eClinical Solutions Division along with Safety and Regulatory Solutions.

Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a post-approval research division.
 

Videos 

News: Bioclinica blogs 
  • SCDM 2018 in Review: Experience, Inspire, Advance October 18, 2018 5:08pm

    Attending SCDM's 2018 Annual Conference in Seattle allowed me to combine some of my passions — travel, learning and knowledge-sharing — into one wonderful sojourn. Themed 'Experience, Inspire and Advance,' this year's program and beautiful Pacific Northwest location didn't disappoint. Below are some thoughts I'd like to share on the conference through the lens of "must-see" city sights in parallel with the program content. Experience: People and Pike Place Market Touring Pike Place Market...
    View this post

  • Transformational Trends in Investigator Site Payments October 1, 2018 12:16pm

    At this year's DIA, I presented information about the pain points that the clinical trials industry is experiencing with regards to site payments as well as the trends that are currently occurring in this space – based on surveys, interviews and analysis of data in Bioclinica's Site & Patient Payments technology. One of these surveys was distributed by FierceBiotech in April, in which we asked sponsors about their challenges and experiences with site payments (149 sponsor companies complet...
    View this post

  • Clinical Supply Chain Success: Leveraging Technology September 26, 2018 10:19am

    The availability of investigational product often determines the success of a clinical trial's randomization and trial supply management (RTSM) solution. RTSM solutions are a key component of the clinical supply chain, the purpose of which is to ensure that the correct investigational product is at the right site at the right time for a subject. When the clinical supply chain fails to achieve this goal, the subjects as well as the entire study are affected. Maintaining the right balance between...
    View this post

  • Preparing for Upcoming FDA Guidance on Blood Pressure (BP) Response in Clinical Trials August 31, 2018 10:22am

    — Part 2 in a 3-part blog series on cardiac safety regulatory developments In my last blog, FDA Issues Draft Guidance on Blood Pressure (BP) Response in Clinical Trials, we looked at the FDA's draft guidance Assessment of Pressor Effects of Drugs Guidance for Industry issued in May 2018. In this blog post you'll find answers to commonly asked questions along with additional background and BP safety endpoint considerations to help drug developers prepare for the new FDA BP guidance, which may...
    View this post

  • How Did Trial Supply Optimization Technology Enable Novo Nordisk to Reduce Drug Supply Waste? August 28, 2018 3:33pm

    Despite the high costs associated with either too little drug supply (risking both patient and study outcomes) or too much drug supply (wasting excess or expired drug), as an industry, we have historically been hampered by our ability to accurately forecast how much drug we will need and when and where we will need it. It's a difficult balance to achieve – providing adequate stocks throughout the entire trial while reducing waste – and often results in overstocking to avoid insufficient supp...
    View this post

  • FDA Issues Draft Guidance on Blood Pressure (BP) Response in Clinical Trials August 13, 2018 1:23pm

    Preparing for new BP guidance Part 1 in a 3-part blog series on recent cardiac safety regulatory developments New FDA draft guidance on blood pressure response released in May 2018, entitled: Assessment of Pressor Effects of Drugs Guidance for Industry, is intended to help address blood pressure effect in drug development. If not already familiarized with it, now is a good time to do so as the final guidance — expected to be issued in as early as the first quarter of 2019 — carries importan...
    View this post

Information

  • Bioclinica

    United States
    Map It »
    www.bioclinica.com
  • Videos1
  • News6
  • Last UpdatedJune 30, 2017 9:21am EDT

Connect

Contacts